Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
How tertiary lymphoid structures predict pembrolizumab response in soft-tissue sarcoma — and why plasma cells matter
Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
Background In the era of immuno-oncology, identifying primary resistance mechanisms to immune checkpoint inhibitors remains crucial. A better understanding of these mechanisms may help to identify novel pathways that can be targeted to improve response rates, as well as biomarkers that could support the selection of patients more likely to benefit from cancer immunotherapies. Among […]
Why intratumoral CD163+ macrophages predict anti-PD-1 resistance in non-small cell lung cancer
Why IDO1 inhibitors failed in the clinic — and what’s next for targeting tryptophan metabolism in cancer
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
Which biliary tract cancers benefit from regorafenib–avelumab — and which biomarkers matter?
Can trabectedin plus durvalumab help platinum-resistant ovarian carcinoma and soft tissue sarcoma?
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
